Company: BSX
Filing Date: 2025-02-18
Form Type: 10-K
Source: 0000885725-25-000011
Chunk: 146

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-02-18
Form: 10-K
Item: Item 8
Chunk 146
---
 operations, as well as revenue and cash flow projections associated with future technologies, none of which is deductible for tax purposes.

82

We allocated a portion of the purchase price to the specific intangible asset categories as follows:Amount Assigned(in millions)Weighted Average Amortization Period(in years)Risk-Adjusted Discount Rates used in Purchase Price AllocationAcotec:Amortizable intangible assets:Technology-related$308 1114%Customer relationships15 1114%Other intangible assets11 1314%$334 Apollo:Amortizable intangible assets:Technology-related$222 1112%Customer relationships26 1112%$248 Relievant:Amortizable intangible assets:Technology-related$287 1212%Customer relationships38 1212%$325 Our technology-related intangible assets consist of technical processes, intellectual property and institutional understanding with respect to products and processes that we intend to leverage in future products or processes. We used the multi-period excess earnings method, a form of the income approach, to derive the fair value of the technology-related intangible assets and are amortizing them on a straight-line basis over their assigned estimated useful lives.Contingent ConsiderationChanges in the fair value of our contingent consideration liability during 2024 and 2023 associated with current and prior period acquisitions were as follows:(in millions)Balance as of December 31, 2022$149 Amount recorded related to current year acquisitions273 Contingent consideration net expense (benefit)58 Contingent consideration payments(76)Balance as of December 31, 2023$404 Amount recorded related to current year acquisitions29 Contingent consideration net expense (benefit)(5)Contingent consideration payments and other adjustments(257)Balance as of December 31, 2024$171 In 2024, payments were primarily related to our acquisition of Farapulse, Inc. (Farapulse) and Relievant following the achievement of revenue-based earnouts and sales milestones, respectively. In 2023, payments were primarily related to our acquisition of Farapulse following the achievement of revenue milestones.

83

The maximum amount for certain contingent consideration is not determinable as it is uncapped and based on a percent of certain sales. As of December 31, 2024, the fair value of such uncapped contingent consideration is estimated at $147 million. As of December 31, 2024, the maximum amount that we could be required